Sales growth was at a record high in FY18/19 on the back of new product launches in the ophthalmic devices and microsurgery segments. While the EBIT margin also touched new highs, driven by operational leverage and favourable product mix, profitability was partly held back by higher investments in R&D/digitalisation. As the addressable market offers significant growth opportunities, management would pump substantial money into R&D, along with increased sales and marketing spend. Ergo,
09 Dec 2019
FY18/19 a record year; margin expansion to slowdown in the mid-term
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
FY18/19 a record year; margin expansion to slowdown in the mid-term
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
09 Dec 2019 -
Author:
Sumit Sayal -
Pages:
3
Sales growth was at a record high in FY18/19 on the back of new product launches in the ophthalmic devices and microsurgery segments. While the EBIT margin also touched new highs, driven by operational leverage and favourable product mix, profitability was partly held back by higher investments in R&D/digitalisation. As the addressable market offers significant growth opportunities, management would pump substantial money into R&D, along with increased sales and marketing spend. Ergo,